Tagged with AI

Pharma Legal Handbook What are the regulatory requirements for traditional, herbal, complementary, or alternative medicines and devices? In April 2019, the Thai FDA published and implemented the Herbal Product Act. This is now the main act regulating herbal or traditional medicine in Thailand. The authorization process for the marketing of traditional medicines and…

Pharma Legal Handbook What types of liability are recognized in your jurisdiction? The laws of Thailand provide for civil, criminal, and administrative liabilities. Fundamentally, product liability is recognized as part of sales and contract law wherein the seller shall be liable to the buyer for a damage caused by deficient goods. This liability…

Pharma Legal Handbook What are the basic requirements to obtain patent and trademark protection? Patent The “subject matter” contained in a patent application may be patented if the following requirements are met: Novelty: Before the filing date, the subject matter must not have been publicly used anywhere in Thailand, and the details of…

Pharma Legal Handbook Are there proposals for reform or significant change to the healthcare system? Significant changes to the healthcare system include the following: The Patent Act The Patent Act is currently under review and final revision by the Department of Intellectual Property, and is expected to be passed soon. The Act’s amendments…

Pharma Legal Handbook Are there any rules or regulations requiring and/or encouraging localization in your country? What is the legal framework defining these localization rules and policies? Yes. Pursuant to Section 12 of the Drug Act 1967, as amended, any domestic manufacturing, importing or ordering into Thailand, including the distributing of active pharmaceutical…

Pharma Legal Handbook Chapter 9: Cannabinoid Drugs Are Cannabinoid Drugs authorized in your country? For the purpose of this chapter, cannabinoid drugs are drugs containing a cannabinoid, which may be extracted and purified from a cannabis plant or synthesized by other means without involving a cannabis plant. The formulations of cannabinoid drugs may…

Pharma Legal Handbook What is the definition of Rare Diseases in your country? Neither the Ministry of Public Health in Thailand (MoPH) nor the Thai Food and Drug Administration (Thai FDA) has prescribed a definition for “rare diseases.” However, the Unit of Clinical Genetics, Department of Paediatrics, Faculty of Medicine at Mahidol University,…

Global Traditional drug discovery is fraught with failure and often like trying to find a needle in a haystack. Even once a candidate is identified, the development process takes thousands of man-hours and generally billions of dollars. Artificial Intelligence has the potential to change this paradigm. It can aggregate and synthesize…

Global Almost 2,500 attendees flocked to Madrid last week for the 2024 edition of Clinical Trials on Alzheimer’s Disease (CTAD). The first European edition of the conference since 2018 was punctuated by a mood of excitement, with Leqembi (lecanemab) – the second drug that targets Alzheimer’s disease progression by reducing amyloid…

Puerto Rico Ivan Lugo-Montes emphasizes the Puerto Rico Bioscience Cluster (INDUNIV)’s instrumental role in advancing the island’s biosciences industry for over 60 years. Driven by innovation, workforce development, and global competitiveness, the Cluster has achieved significant milestones in advanced manufacturing, pharmaceutical cold chain logistics certification, business promotion, and international partnerships. Key initiatives…

USA Naming a Chief Artificial Intelligence (AI) officer may not be an industry first, but Lilly’s recent creation of the role with the appointment of Thomas Fuchs confirms the solid commitment pharma has already made to introducing AI in processes that range from drug discovery to marketing.   AI Leaders Eli…

India Contributing to the October 2024 edition of DIA’s Global Forum magazine, Stephanie Rosner of DIA and Martin Hodosi and Rosanna Lim of Kearney highlight the discussions from DIA’s multistakeholder Responsible AI Solution Room, which focused on cross-sector partnerships for responsible AI use and strategies to mitigate AI risk.   Artificial…